EU clears Biogen’s Spinraza for rare spinal disorder

2nd June 2017 Uncategorised 0

EU regulators have issued clearance for the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.

More: EU clears Biogen’s Spinraza for rare spinal disorder
Source: News